Research programme: superoxide dismutase 1 target therapeutics - Thera Neuropharma

Drug Profile

Research programme: superoxide dismutase 1 target therapeutics - Thera Neuropharma

Alternative Names: RNA interference-based therapeutics - Thera Neuropharma; sd-rxRNA® based therapeutics - Thera Neuropharma; SOD1 targeting sd-rxRNA therapeutics - Thera Neuropharma; THN 1

Latest Information Update: 11 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Thera Neuropharma
  • Developer RXi Pharmaceuticals; Thera Neuropharma
  • Class Small interfering RNA; Small molecules
  • Mechanism of Action RNA interference; Superoxide dismutase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 03 May 2016 Preclinical trials in Amyotrophic lateral sclerosis in USA (Parenteral)
  • 03 May 2016 Thera Neuropharma and RXi Pharmaceuticals have jointly files for patent protection for the management of neurodegenerative diseases associated with SOD1 in USA
  • 03 May 2016 Thera Neuropharma in-licenses self-delivering RNAi (sd-rxRNA®) platform targeting SOD1 technology from RXi Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top